Literature DB >> 10792993

HIV-1 replication is inhibited by a pseudo-substrate peptide that blocks Tat transactivation.

H Okamoto1, T P Cujec, B M Peterlin, T Okamoto.   

Abstract

The activation of the HIV-1 long terminal repeat (LTR) by the viral transcriptional transactivator Tat is an essential step in the viral replication cycle. To increase the processivity of RNA polymerase II, Tat interacts with the positive transcription elongation factor b (P-TEFb) and cyclin-dependent kinase (CDK)-activating kinase (CAK). In this study, we demonstrate that a pseudo-substrate peptide for CDK7, mC2p, inhibits HIV-1 replication as well as Tat transactivation. Specifically, mC2p blocks only the activity of CAK and not that of P-TEFb. Moreover, mC2p inhibits Tat transactivation and HIV replication. Therefore, the activation of CDK7 by Tat is considered a critical step of Tat transactivation and mC2p and related compounds represent potential candidates for novel anti-HIV therapeutics. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10792993     DOI: 10.1006/viro.2000.0311

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  5 in total

1.  Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors.

Authors:  D Wang; C de la Fuente; L Deng; L Wang; I Zilberman; C Eadie; M Healey; D Stein; T Denny; L E Harrison; L Meijer; F Kashanchi
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Autophagy restricts HIV-1 infection by selectively degrading Tat in CD4+ T lymphocytes.

Authors:  Sophie Sagnier; Coralie F Daussy; Sophie Borel; Véronique Robert-Hebmann; Mathias Faure; Fabien P Blanchet; Bruno Beaumelle; Martine Biard-Piechaczyk; Lucile Espert
Journal:  J Virol       Date:  2014-10-22       Impact factor: 5.103

3.  The immunosuppressant rapamycin represses human immunodeficiency virus type 1 replication.

Authors:  Jocelyn Roy; Jean-Sébastien Paquette; Jean-François Fortin; Michel J Tremblay
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

4.  Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins.

Authors:  Luis M Schang; Andrew Bantly; Marie Knockaert; Farida Shaheen; Laurent Meijer; Michael H Malim; Nathanael S Gray; Priscilla A Schaffer
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

5.  Tyrosine kinases in rheumatoid arthritis.

Authors:  Hiroshi Okamoto; Akiko Kobayashi
Journal:  J Inflamm (Lond)       Date:  2011-08-24       Impact factor: 4.981

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.